Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275

2020; American Association for Cancer Research; Volume: 26; Issue: 19 Linguagem: Inglês

10.1158/1078-0432.ccr-19-4162

ISSN

1557-3265

Autores

Matthew D. Galsky, Abdel Saci, Péter M. Szabó, G. Celine Han, Gary D. Grossfeld, Sandra Collette, Arlene O. Siefker‐Radtke, Andrea Necchi, Padmanee Sharma,

Tópico(s)

Urinary and Genital Oncology Studies

Resumo

We report efficacy and safety with extended follow-up, and exploratory biomarker analyses from the phase II CheckMate 275 trial to identify biomarkers of response to nivolumab in platinum-resistant metastatic or unresectable urothelial carcinoma (mUC).

Referência(s)